Rheumatoid arthritis

著者

書誌事項

Rheumatoid arthritis

edited by Gary S. Firestein, Gabriel S. Panayi and Frank A. Wollheim

Oxford University Press, 2006

2nd ed.

大学図書館所蔵 件 / 全2件

この図書・雑誌をさがす

注記

Includes bibliographical references and index

内容説明・目次

内容説明

Rheumatoid arthritis (RA) is a chronic inflammatory disease, which affects 1% of the world's population. Patients with RA not only have a progressive and debilitating disease and severe functional impairment, but can also experience a reduced life expectancy due to frequent involvement of the major organ systems. This new edition of Rheumatoid Arthritis charts the profound changes in research and patient management that have taken place over the last 5 years. Developments in molecular biology have dramatically increased insight into the inflammatory and destructive pathways of this complex disease. Over half a million patients have been successfully treated with biologic therapy and advances in imaging techniques have allowed increasingly early detection of disease onset. Rheumatoid factor is no longer the unchallenged gold standard autoantibody but has competition from the anti-citrulline antibodies. Environmental factors influencing both susceptibility and progression have been sought, and smoking has emerged as a powerful factor. Steady progress in genetics is finally being made and one day it may be possible to predict RA before onset of symptomatic disease. It is against this backdrop of dynamic developments that the new edition of Rheumatoid Arthritis publishes.

目次

  • Preface
  • SECTION 1
  • Etiology
  • 1. Genetics of rheumatoid arthritis
  • 2. Epidemiology and determinants of susceptibility
  • 3. Microbes in the pathogenesis of rheumatoid arthritis
  • 4. Experimental models for rheumatoid arthritis
  • SECTION 2
  • Mechanisms of inflammation
  • 5. The role of macrophages in rheumatoid arthitis
  • 6. The role of T lymphocytes in rheumatoid arthritis
  • 7. The role of neutrophils in the pathogenesis of rheumatoid arthritis
  • 8. The role of fibroblast-like synoviocytes in rheumatoid arthritis
  • 9. The roles of B cells in rheumatoid arthritis
  • 10. Innate immunity and immune complexes in rheumatoid arthritis
  • 11. Angiogenesis and cell trafficking
  • 12. Cytokine networks
  • 13. Autoantibodies in rheumatoid arthritis
  • 14. Mechanisms of fibroblast-mediated joint destruction
  • 15. Pain mechanisms in rheumatoid arthritis
  • 16. The stress system and the hypothalamic-pituitary adrenal (HPA) axis in rheumatoid arthritis
  • SECTION 3
  • Clinical Aspects
  • 17. Examination of the synovium and synovial fluid
  • 18. Clinical aspects of rheumatoid arthritis
  • 19. Imaging in rheumatoid arthritis
  • 20. Susceptibility, prognosis & mortality
  • 21. Biomarkers for cartilage and bone in rheumatoid arthritis
  • SECTION 4
  • Drug Therapy
  • 22. NSAIDS and analgesics
  • 23. Systemic and intra-articular glucorticoids in rheumatoid arthritis
  • 24. Methotrexate and Leflunomide
  • 25. Gold, antimalarials, sulfasalazine, and other DMARDS
  • 26. Combination therapy with synthetic DMARDs in the treatment of rheumatoid arthritis
  • 27. Biologics in the treatment of rheumatoid arthritis
  • SECTION 5
  • Non-Drug Therapy
  • 28. The impact of physiotherapy
  • 29. Patient Education
  • 30. Occupation therapy and assistive products and technology
  • 31. Psychological and social aspects
  • 32. Pain management
  • 33. Health economics
  • SECTION 6
  • Surgical Therapy
  • 34. Large joints and feet
  • 35. The hand
  • 36. The cervical spine
  • SECTION 7
  • Frontiers of Therapy
  • 37. Design of trials involving clinical endpoints
  • 38. Clinical trials with imaging and biomark endpoints
  • 39. New biologics: cytokines
  • 40. New biologics: T and B cell modulators
  • 41. Inhibibition of proteolytic activity involved in cartilage breakdown
  • 42. Signal transduction in rheumatic diseases
  • 43. Mesenchymal stem cells in arthritis

「Nielsen BookData」 より

詳細情報

ページトップへ